Detalhe da pesquisa
1.
[The cancer registry notification seen from the perspective of the German Society of Uro-Oncologists (d-uo)]. / Die Krebsregistermeldung aus der Sicht der Deutschen Uro-Onkologen (d-uo).
Aktuelle Urol
; 54(3): 189-195, 2023 06.
Artigo
em Alemão
| MEDLINE | ID: mdl-37224856
2.
[Real-world data on prostate cancer: the VERSUS trial by d-uo]. / Ergebnisse aus der VERSUS-Studie von d-uo am Beispiel des Prostatakarzinoms.
Aktuelle Urol
; 54(3): 196-201, 2023 06.
Artigo
em Alemão
| MEDLINE | ID: mdl-37224857
3.
[National Registries for Urothelial Cancer (UroNAT) and Prostate Cancer (ProNAT) by d-uo]. / Nationale Register Urothelkarzinom (UroNAT) und Prostatakarzinom (ProNAT) von d-uo.
Aktuelle Urol
; 54(3): 202-207, 2023 06.
Artigo
em Alemão
| MEDLINE | ID: mdl-37224858
4.
[Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo]. / Osteoprotektion beim nichtmetastasierten hormonsensitiven Prostatakarzinom (nmHSPC) unter androgendeprivativer Therapie (ADT): Aktuelle Daten aus Deutschland, vorgelegt von d-uo.
Aktuelle Urol
; 53(6): 517-525, 2022 12.
Artigo
em Alemão
| MEDLINE | ID: mdl-36423612
5.
[Osteoprotection in patients with bone metastatic castration-resistant prostate cancer (mCRPC): real-world data from Germany, presented by d-uo]. / Osteoprotektion beim ossär metastasierten kastrationsresistenten Prostatakarzinom (mCRPC): Aktuelle Daten aus Deutschland, vorgelegt von d-uo.
Aktuelle Urol
; 53(6): 526-534, 2022 12.
Artigo
em Alemão
| MEDLINE | ID: mdl-36423613
6.
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride]. / Retrospektive Versorgungsstudie von d-uo zur Therapie des mCRPC mit Radium-223-dichlorid.
Aktuelle Urol
; 53(6): 511-516, 2022 12.
Artigo
em Alemão
| MEDLINE | ID: mdl-36167310
7.
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Prostate Cancer Prostatic Dis
; 25(4): 778-784, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35430584
8.
Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting.
Front Oncol
; 11: 655355, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34123810
9.
Stadien des Prostatakarzinoms und Unmet Medical Need.
Oncol Res Treat
; 42 Suppl 2: 2-3, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30959511
10.
Urologische Versorgungsforschung in Deutschland: Auf einem guten Weg!
Aktuelle Urol
; 54(3): 165-166, 2023 06.
Artigo
em Alemão
| MEDLINE | ID: mdl-37224846
11.
Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.
J Cancer Res Clin Oncol
; 144(3): 571-577, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29299751
12.
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Prostate Cancer Prostatic Dis
; 26(4): 812, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37253975
13.
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride]. / Erratum: Retrospektive Versorgungsstudie von d-uo zur Therapie des mCRPC mit Radium-223-dichlorid.
Aktuelle Urol
; 53(6): e2, 2022 Dec.
Artigo
em Alemão
| MEDLINE | ID: mdl-36279875